Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.36 USD
+0.54 (0.58%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.36 USD
+0.54 (0.58%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Acadia (ACAD) Up 3.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Up 3.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
by Zacks Equity Research
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 11.16% and 51.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
by Zacks Equity Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on sales numbers of Pfizer's (PFE) COVID-19 vaccine and COVID pill, Paxlovid.
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) third-quarter sales.
Analysts Estimate GSK (GSK) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
by Zacks Equity Research
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
by Zacks Equity Research
Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.
Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reata Pharmaceuticals, Inc. (RETA) Up 4.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Regeneron (REGN) Down 2.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines (BPMC) Up 22.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Thrives on Qinlock, Overdependence a Concern
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. However, heavy dependence on Qinlock for growth remains a woe.
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study
by Zacks Equity Research
Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.
Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
by Zacks Equity Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.